MEET OUR SAB MEMBERS
experts which provide valuable expertise and help shaping the programm and protfolio
Steven Boxer is the Camille and Henry Dreyfus Distinguished Professor in the Department of Chemistry at Stanford University. His research interests are in biophysics: the interface of physical chemistry, biology and engineering. Topics of current interest include: electrostatics and dynamics in proteins; excited state dynamics of green fluorescent protein, especially split GFP, with applications in biotechnology; electron and energy transfer mechanisms in photosynthesis; and the fabrication of artificial systems to simulate, manipulate and image biological membranes. He has served on the scientific advisory board of many start-ups in the general area of biotechnology, and as an advisor to the Howard Hughes Medical Institute, the National Institutes of Health and the National Science Foundation. He is the recipient of several awards, and is an elected Fellow of the American Academy of Arts and Sciences, the Biophysical Society and the National Academy of Sciences.
Dr. Myers is a biochemist with a wealth of experience in genomics and product development. He received his PhD in Molecular Pharmacology from Stanford University School of Medicine in 2005 where he developed and commercialized an RNA interference (RNAi) technology with Ambion, Invitrogen, and Roche. This innovative RNAi technology named In Vitro Dicing was widely used, especially in high-throughput and high-content loss-of-function screening studies, because it was the least expensive, most efficient, and most effective gene silencing method available. Dr. Myers received funding from the American Cancer Society and Canary Foundation to complete three years of post-doctoral training at Stanford University in the Department of Biochemistry. During his post-doctoral fellowship he developed novel microarray-based methods and software to investigate genome-wide regulation of post-transcriptional gene expression. Shortly after the semiconductor sequencing company Ion Torrent was formed Dr. Myers joined and worked with the team to develop the novel sequencing chemistry and system. Subsequently he led a cross-functional product development team dedicated to collaborations with thought-leading customers to further develop the Ion Torrent technology and sequencing applications. In 2013 Dr. Myers co-founded ArcherDx Inc. with Dr. A. John Iafrate and Dr. Long P. Le to develop NGS-based assays for clinical oncology. Later in 2013 he joined Enzymatics as Chief Scientific Officer through the acquisition of ArcherDx by Enzymatics Inc. In 2015, Dr. Myers reassumed the role of CEO at ArcherDX after the acquisition of specific assets of Enzymatics by Qiagen.
Wake-Forest University, School of Biomedical Engineering and Sciences,
Ph.D., Applied and Materials Sciences, University of North Carolina at Chapel Hill